First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ: TRAX · Real-Time Price · USD
37.37
+0.50 (1.36%)
At close: Jul 21, 2026, 4:00 PM EDT
36.70
-0.67 (-1.79%)
After-hours: Jul 21, 2026, 4:16 PM EDT
First Tracks Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A newly independent biotech with $180 million in cash is advancing a pipeline of antibody therapies for autoimmune diseases, led by ANB033 targeting CD122. Key phase I-B trials in celiac disease and EoE are ongoing, with major data readouts expected in Q4 and mid-2027.